|Bid||77.31 x 1000|
|Ask||0.00 x 900|
|Day's range||77.48 - 78.67|
|52-week range||69.10 - 95.19|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||36.86|
|Forward dividend & yield||0.98 (1.25%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||N/A|
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter’s Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and chief executive officer, Owens-Illinois, Inc., and a Baxter director since 2004, as its lead independent director. Mr. Stroucken, who previously served as the chairman of the Audit Committee, will succeed Thomas T. Stallkamp, who has served as lead independent director from May 2014 to February 2021. Mr. Stallkamp will continue to serve as a director of the board. Both new appointments are effective today and will bring the total number of directors serving the company to 13.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on April 1, 2021, to shareholders of record as of February 26, 2021. The indicated annual dividend rate is $0.98 per share of common stock.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidance for 2021.